Discussion stirs around Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) this week; here is what analysts are saying.

May 16, 2018 - By Dolores Ford

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) LogoInvestors sentiment decreased to 1.34 in Q4 2017. Its down 0.28, from 1.62 in 2017Q3. It dropped, as 53 investors sold Vertex Pharmaceuticals Incorporated shares while 160 reduced holdings. 72 funds opened positions while 213 raised stakes. 232.48 million shares or 0.46% more from 231.42 million shares in 2017Q3 were reported.
Bridgeway Mgmt has 49,300 shares for 0.08% of their portfolio. Moreover, State Street has 0.13% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Tarbox Family Office invested 0.02% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). American Research And Mngmt reported 8,900 shares. Highland Capital Management Lp owns 1,500 shares for 0.01% of their portfolio. 2,074 are held by Keybank National Association Oh. Korea Corp has invested 0.07% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Hbk L P accumulated 136,705 shares or 0.19% of the stock. Fincl Bank Of Nova Scotia reported 39,709 shares. Mitsubishi Ufj Holdg Limited holds 0.39% or 630 shares. Johnson Gru owns 28 shares. Retail Bank Of Montreal Can holds 0.05% or 348,499 shares. Quantres Asset Mngmt Limited invested in 2,100 shares. Bokf Na holds 0.01% or 1,856 shares in its portfolio. Rnc Capital Ltd Com owns 1,934 shares.

Since December 11, 2017, it had 0 buys, and 44 selling transactions for $106.32 million activity. Sachdev Amit had sold 46,172 shares worth $7.33 million on Friday, January 19. Graney Thomas sold $116,511 worth of stock or 777 shares. On Tuesday, January 16 LEIDEN JEFFREY M sold $15.63M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 99,563 shares. 2,125 shares were sold by Arbuckle Stuart A, worth $346,396 on Monday, April 16. 6,403 shares were sold by ALTSHULER DAVID, worth $965,671. Silva Paul M had sold 9,883 shares worth $1.71M on Thursday, February 1.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 18 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 18 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vertex Pharmaceuticals had 25 analyst reports since December 12, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, February 1 by Piper Jaffray. The firm has “Overweight” rating given on Friday, April 27 by Morgan Stanley. RBC Capital Markets maintained the shares of VRTX in report on Wednesday, April 4 with “Buy” rating. The rating was maintained by JMP Securities on Tuesday, December 12 with “Buy”. On Monday, March 5 the stock rating was maintained by Maxim Group with “Buy”. The stock has “Market Outperform” rating by JMP Securities on Tuesday, February 13. Guggenheim maintained the shares of VRTX in report on Wednesday, January 31 with “Buy” rating. Leerink Swann maintained it with “Buy” rating and $190.0 target in Thursday, February 1 report. Robert W. Baird maintained it with “Buy” rating and $200.0 target in Wednesday, January 31 report. The firm has “Buy” rating given on Thursday, February 1 by Barclays Capital. Below is a list of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) latest ratings and price target changes.

27/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $200 New Target: $207 Maintain
27/04/2018 Broker: Oppenheimer Rating: Buy New Target: $190.0000 Maintain
04/04/2018 Broker: RBC Capital Markets Rating: Buy New Target: $199.0000 Maintain
13/03/2018 Broker: Cowen & Co Rating: Buy New Target: $200.0 Maintain
05/03/2018 Broker: Maxim Group Old Rating: Buy New Rating: Buy Old Target: $195 New Target: $200 Maintain
23/02/2018 Broker: Argus Research Rating: Buy New Target: $194.0
13/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $200 New Target: $211 Maintain
13/02/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $195 New Target: $196 Maintain
02/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $198 New Target: $200 Maintain
01/02/2018 Broker: Oppenheimer Rating: Buy New Target: $190.0 Upgrade

The stock increased 0.40% or $0.62 during the last trading session, reaching $156.16. About 971,857 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 76.59% since May 16, 2017 and is uptrending. It has outperformed by 65.04% the S&P500.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $39.79 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 150.3 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Fool.com which released: “3 Top Biotech Stocks to Buy in May” on May 09, 2018, also Fool.com with their article: “Vertex Pharmaceuticals Takes a Detour Around the FDA’s Roadblock” published on April 30, 2018, Streetinsider.com published: “Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies – RBC” on May 15, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery …” published on May 10, 2018 as well as Seekingalpha.com‘s news article titled: “Vertex Pharmaceuticals Heads Toward An Important Tipping Point” with publication date: May 01, 2018.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.